Shaanxi Micot Pharmaceutical Technology (HKG:2335) concluded the phase II clinical trial of MT200605 for the treatment of AIS, according to a Wednesday Hong Kong bourse filing.
Shares of the Chinese biotechnology company were up nearly 2% in Thursday afternoon trading.
The trial demonstrated significant and robust efficacy advantages with a favorable safety profile.